Attitudes of patients and physicians on repeat biopsies for lung cancer

References

• Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448:561–566.
   Google Scholar
• Arteaga CL. The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. J Clin Oncol. 2001;19:32S–40S.
   Google Scholar
• Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949–954.
   Google Scholar
• Hirsh V, Melosky B, Goss G, et al. A personalized approach to treatment: use of EGFR tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer in Canada. Curr Oncol. 2012;19:78–90.
   Google Scholar
• Niikura N, Liu J, Hayashi N, et al. Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors. J Clin Oncol. 2012;30:593–599.
   Google Scholar
• Amir E, Miller N, Geddie W, et al. Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer. J Clin Oncol. 2012;30:587–592.
   Google Scholar
• Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012;366:883–892.
   Google Scholar
• Vaz-Luis I, Zeghibe CA, Frank ES, et al. Prospective clinical experience with research biopsies in breast cancer patients. Breast Cancer Res Treat. 2013;142:203–209.
   Google Scholar
• Gancberg D, Di Leo A, Cardoso F, et al. Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites. Ann Oncol. 2002;13:1036–1043.
   Google Scholar
• Peppercorn J. Toward improved understanding of the ethical and clinical issues surrounding mandatory research biopsies. J Clin Oncol. 2013;31:1–2.
   Google Scholar
• Janne PA, Yang JC, Kim DW, et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med. 2015;372:1689–1699.
   Google Scholar
• Oxnard GR, Paweletz CP, Kuang Y, et al. Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA. Clin Cancer Res. 2014;20:1698–1705.
   Google Scholar
• Haringsma HJAA, Harding TC, Simmons AD. In vivo acquired resistance to the mutant EGFR inhibitor rociletinib (CO-1686) is associated with activation of the c-MET pathway. Publisher: Elsevier. In abstr 3595. 2015.
   Google Scholar
• Chabon JJ, Simmons A, Newman AM, et al. Inter- and intra-patient heterogeneity of resistance mechanisms to the mutant EGFR selective inhibitor rociletinib. ASCO Annual Meeting: J Clin Oncol. 201634:15_suppl, 9000-9000.
   Google Scholar
• Thress KS, Paweletz CP, Felip E, et al. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat Med. 2015;21:560–562.
   Google Scholar
• Kim EY, Cho EN, Park HS, et al. Genetic heterogeneity of actionable genes between primary and metastatic tumor in lung adenocarcinoma. BMC Cancer. 2016;16:27.
   Google Scholar
• Gainor JF, Dardaei L, Yoda S, et al. Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer. Cancer Discov. 2016;6:1118–1133.
   Google Scholar
• Shaw AT, Friboulet L, Leshchiner I, et al. Resensitization to crizotinib by the lorlatinib ALK resistance mutation L1198F. N Engl J Med. 2016;374:54–61.
   Google Scholar
• Seah DS, Scott SM, Najita J, et al. Attitudes of patients with metastatic breast cancer toward research biopsies. Ann Oncol. 2013;24:1853–1859.
   Google Scholar
• Peppercorn J, Shapira I, Collyar D, et al. Ethics of mandatory research biopsy for correlative end points within clinical trials in oncology. J Clin Oncol. 2010;28:2635–2640.
   Google Scholar
• McLachlan S-A, Clements A, Austoker J. Patients’ experiences and reported barriers to colonoscopy in the screening context–a systematic review of the literature. Patient Educ Couns. 2012;86:137–146.
   Google Scholar
• Daugherty C, Ratain MJ, Grochowski E, et al. Perceptions of cancer patients and their physicians involved in phase I trials. J Clin Oncol. 1995;13:1062–1072.
   Google Scholar
• Cohen H, Britten N. Who decides about prostate cancer treatment? A qualitative study. Fam Pract. 2003;20:724–729.
   Google Scholar
• Gage-Bouchard EA, Rodriguez EM, Saad-Harfouche FG, et al. Factors influencing patient pathways for receipt of cancer care at an NCI-designated comprehensive cancer center. Plos One. 2014;9:e110649.
   Google Scholar
• Jenkins V, Fallowfield L. Reasons for accepting or declining to participate in randomized clinical trials for cancer therapy. Br J Cancer. 2000;82:1783–1788.
   Google Scholar
• Gravel K, Legare F, Graham ID. Barriers and facilitators to implementing shared decision-making in clinical practice: a systematic review of health professionals’ perceptions. Implement Sci. 2006;1:16.
   Google Scholar
• Jimenez R, Zhang B, Joffe S, et al. Clinical trial participation among ethnic/racial minority and majority patients with advanced cancer: what factors most influence enrollment? J Palliat Med. 2013;16:256–262.
   Google Scholar
• Mahipal A, Nguyen D. Risks and benefits of phase 1 clinical trial participation. Cancer Control. 2014;21:193–199.
   Google Scholar
• Overman MJ, Modak J, Kopetz S, et al. Use of research biopsies in clinical trials: are risks and benefits adequately discussed? J Clin Oncol. 2013;31:17–22.
   Google Scholar
• El-Osta H, Hong D, Wheler J, et al. Outcomes of research biopsies in phase I clinical trials: the MD Anderson Cancer Center experience. Oncologist. 2011;16:1292–1298.
   Google Scholar
• Agulnik M, Oza AM, Pond GR, et al. Impact and perceptions of mandatory tumor biopsies for correlative studies in clinical trials of novel anticancer agents. J Clin Oncol. 2006;24:4801–4807.
   Google Scholar
• Murtaza M, Dawson SJ, Tsui DW, et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature. 2013;497:108–112.
   Google Scholar
• Jing CW, Wang Z, Cao HX, et al. High resolution melting analysis for epidermal growth factor receptor mutations in formalin-fixed paraffin-embedded tissue and plasma free DNA from non-small cell lung cancer patients. Asian Pac J Cancer Prev. 2014;14:6619–6623.
   Google Scholar
• Zhang H, Liu D, Li S, et al. Comparison of EGFR signaling pathway somatic DNA mutations derived from peripheral blood and corresponding tumor tissue of patients with advanced non-small-cell lung cancer using liquidchip technology. J Mol Diagn. 2013;15:819–826.
   Google Scholar
• Kim ST, Lee WS, Lanman RB, et al. Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients. Oncotarget. 2015;6:40360–40369.
   Google Scholar
• Luo J, Shen L, Zheng D. Diagnostic value of circulating free DNA for the detection of EGFR mutation status in NSCLC: a systematic review and meta-analysis. Sci Rep. 2014;4:6269.
   Google Scholar
• Sundaresan TK, Sequist LV, Heymach JV, et al. Detection of T790M, the acquired resistance EGFR mutation, by tumor biopsy versus noninvasive blood-based analyses. Clin Cancer Res. 2016;22:1103–1110.
   Google Scholar
• Novello S, Capelletto E, Cortinovis D, et al. Italian multicenter survey to evaluate the opinion of patients and their reference clinicians on the “tolerance” to targeted therapies already available for non-small cell lung cancer treatment in daily clinical practice. Transl Lung Cancer Res. 2014;3:173–180.
   Google Scholar
• Pacchiana MV, Capelletto E, Carnio S, et al. Patients’ attitudes and physicians’ perceptions toward maintenance therapy for advanced non-small-cell lung cancer: a multicenter Italian survey. Clin Lung Cancer. 2016. DOI: 10.1016/j.cllc.2016.10.002.
   Google Scholar